HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senate Proposes Smaller Boost Than House For FDA FY2023 Appropriation

Executive Summary

Senate Appropriations Committee proposes $1.185bn to CFSAN and $2.19bn to CDER, both levels short of House appropriators passed in June. FDA requested $30.36m in user fees from monograph drugs but no amount was specified in Senate draft bill.

You may also be interested in...



Senate Budget Draft Would Be Less Generous To US FDA Than House For FY2023

Senate appropriations bill would take back some of increase House offered Center for Drug Evaluation and Research and other FDA programs, setting up negotiations as start of FY2023 nears.

House Has Slim Boost For FDA FY2023 Spending, But Wants Slimmer Budget Document From Agency

Appropriations Committee publishes FY2023 spending bill and report FDA day before it votes on the legislation. It recommends increasing FDA’s budget by less than $400m from its current appropriation to $6.48bn.

House Appropriation Leaders Propose Emergency Funding For FDA's Infant Formula Programs

Democrats introduce bill two days before Agriculture, Rural Development, FDA and Related Agencies subcommittee will question FDA Commissioner Robert Califf about agency’s oversight of formula industry during a hearing on FY2023 budget.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS152804

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel